Tier 2 — strong

Beneficial effects of glycine (bioglycin) on memory and attention in young and middle-aged adults

File SE, Fluck E, Fernandes C
Journal of clinical psychopharmacology 1999 19(6):506-512

Bibliography

PubMed
PMID 10587285
DOI
10.1097/00004714-199912000-00004
Funding
Funding was not specified in the indexed abstract; the full funding disclosure has not been verified.
Competing interests
The accessible abstract does not establish the authors' competing interests; absence of a statement is not evidence of no conflicts.

Study snapshot

DesignRandomized controlled human intervention
ModelAdult humans
SampleYoung adults and middle-aged men; exact sample not provided in the indexed abstract
InterventionBioglycin versus placebo; dose and treatment schedule not specified in the indexed abstract
DurationCrossover treatment periods; timing not specified in the indexed abstract
EndpointsEpisodic memory retrieval; Focused, divided and sustained attention; Mood

What the study showed, in plain terms

This older crossover study reported selected memory-retrieval benefits with a specific glycine preparation. Attention effects differed by age and task, so the findings should not be presented as broad cognitive enhancement.

Key findings

  • Episodic memory retrieval improved in both age groups.
  • Focused and divided attention did not improve; sustained attention benefited in the middle-aged group.

What this study can and cannot tell us

Dose, exact enrollment and complete methods require the original full text.

One preparation and selected task findings cannot establish general nootropic effects of every glycine product.

Related papers in the corpus

Tier 2
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments
Buchanan RW et al. · The American journal of psychiatry · 2007
Tier 2
Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia
Potkin SG et al. · The American journal of psychiatry · 1999
Tier 2
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy U et al. · Biological psychiatry · 2004
Tier 2
Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
Heresco-Levy U et al. · Archives of general psychiatry · 1999
Tier 2
Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
Heresco-Levy U et al. · The British journal of psychiatry : the journal of mental science · 1996
Tier 2
Amelioration of negative symptoms in schizophrenia by glycine
Javitt DC et al. · The American journal of psychiatry · 1994

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction